Incyte
INCY on Nasdaq. Incyte sells prescription medicines to patients with cancer and immune diseases. Market value $24.7bn.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Good business, but not cheap right now
Why it could be worth it
What to watch out for
See cheaper Health care stocks on the list
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $2.90 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 80 of 100. Price score: 42 of 100. Our list needs 70 on quality and 60 on price.
$115.87 a share, 30% above its 1-year low
Over the past year the price has ranged from $89.25 to $132.60.
Pays no dividend
Price from Thursday’s close (19 November).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $685 million in the past 12 months, $1.4 billion in the year to December 2025.
| Revenue | |||||
| Revenue | $3.0bn | $3.4bn | $3.7bn | $4.2bn | $5.1bn |
| Operating margin | |||||
| Operating margin | 19.6% | 17.1% | 16.8% | 1.4% | 29.5% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.22bn | 0.22bn | 0.19bn | 0.20bn | 0.20bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 8 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsStrong, 14.0% a year
- Buying back its own sharesYes, 8% fewer since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $1.6 billion last quarter, up 14% on a year ago.
- A loss of $785 million, after a profit of $424 million a year ago.
- It keeps 10 cents of each $1 of sales as operating profit, down from 31 cents a year earlier.
- Spare cash over the past 12 months: $685 million, down from $1.2 billion.
- 1% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $1.2bn |
| March 2025 | $1.1bn |
| June 2025 | $1.2bn |
| September 2025 | $1.4bn |
| December 2025 | $1.5bn |
| March 2026 | $1.3bn |
| June 2026 | $1.7bn |
| September 2026 | $1.6bn |
| Quarter to | Amount |
|---|---|
| December 2024 | $201m |
| March 2025 | $158m |
| June 2025 | $405m |
| September 2025 | $424m |
| December 2025 | $299m |
| March 2026 | $303m |
| June 2026 | $586m |
| September 2026 | -$785m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- 9 February 2027
- Last annual report (10-K)
- 10 February 2026
- Next quarterly (estimated, 10-Q)
- 28 January 2027
Who owns it
6 long-term investors we follow own it, unchanged from 6 last quarter. 858 funds in all.
- Sound Shore ManagementHarry Burn
- Value
- $86m
- Share of fund
- 2.6%
- GMOJeremy Grantham
- Value
- $36m
- Share of fund
- <0.1%
- Delphi ManagementScott Black
- Value
- $699,000
- Share of fund
- 0.7%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Dodge & CoxDodge & Cox investment committee | $1.4bn | 0.7% | Cut |
| LSV Asset ManagementJosef Lakonishok | $467m | 0.8% | Added |
| Sound Shore ManagementHarry Burn | $86m | 2.6% | |
| Gotham Asset ManagementJoel Greenblatt | $82m | 0.2% | Added |
| GMOJeremy Grantham | $36m | <0.1% | |
| Delphi ManagementScott Black | $699,000 | 0.7% |
Largest holders overall
- Baker Bros. Advisors LP$3.5bn
- BlackRock$2.0bnCut
- Dodge & Cox$1.4bnCut
- Vanguard Capital Management$1.2bn
- State Street$1.1bn
- Vanguard Portfolio Management$883m
- AQR Capital Management$603mCut
- Geode Capital Management$537m
- LSV Asset Management$467mAdded
- Invesco$463mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- Julian C. BakerPassive investorat least 15.6%−0.1 pts(filed with 6 related holders)Since 7 May 2026
What they said
Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On May 8, 2026 the Adviser acquired beneficial ownership of 15,000 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer"), as a result of the exercise of 15,000 options…
Read the filing - BlackRock, Inc.Passive investor7.8%Since 30 September 2025
- Vanguard Capital ManagementPassive investor6.3%Since 31 March 2026
- Dodge & CoxPassive investor5.0%−1.2 ptsSince 30 September 2026
- STATE STREET CORPORATIONPassive investor5.0%Since 30 September 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Julian C. Baker Passive investor | at least 15.6%−0.1 pts (filed with 6 related holders) | 7 May 2026 | What they saidItem 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows: On May 8, 2026 the Adviser acquired beneficial ownership of 15,000 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer"), as a result of the exercise of 15,000 options… Read the filing |
BlackRock, Inc. Passive investor | 7.8% | 30 September 2025 | |
Vanguard Capital Management Passive investor | 6.3% | 31 March 2026 | |
Dodge & Cox Passive investor | 5.0%−1.2 pts | 30 September 2026 | |
STATE STREET CORPORATION Passive investor | 5.0% | 30 September 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 8 sold $68m, $68m of it under preset trading plans.
- Stein Steven HCMO & Head of Late-Stage Dev.Soldunder a preset trading plan
- Date
- 16 November 2026
- Shares
- 576
- Price
- $121.98
- Value
- $70,260
- CAGNONI PABLO JPresident, Global Head of R&DSoldunder a preset trading plan
- Date
- 16 November 2026
- Shares
- 2,642
- Price
- $120.96
- Value
- $319,588
- Heeson LeeEVP, Head of Incyte IntlSoldunder a preset trading plan
- Date
- 13 November 2026
- Shares
- 10,694
- Price
- $120.82
- Value
- $1m
- Stein Steven HCMO & Head of Late-Stage Dev.Soldunder a preset trading plan
- Date
- 6 November 2026
- Shares
- 240,193
- Price
- $118.39
- Value
- $28m
- Tray ThomasPrincipal Accounting OfficerSoldunder a preset trading plan
- Date
- 3 November 2026
- Shares
- 610
- Price
- $118.96
- Value
- $72,566
- CAGNONI PABLO JPresident, Global Head of R&DSoldunder a preset trading plan
- Date
- 15 October 2026
- Shares
- 2,642
- Price
- $112.71
- Value
- $297,780
- CAGNONI PABLO JPresident, Global Head of R&DSoldunder a preset trading plan
- Date
- 15 September 2026
- Shares
- 23,218
- Price
- $120.49
- Value
- $3m
- CAGNONI PABLO JPresident, Global Head of R&DSoldunder a preset trading plan
- Date
- 19 August 2026
- Shares
- 10,801
- Price
- $125.56
- Value
- $1m
- CAGNONI PABLO JPresident, Global Head of R&DSoldunder a preset trading plan
- Date
- 12 August 2026
- Shares
- 10,803
- Price
- $120.04
- Value
- $1m
- Mayes Patrick AEVP & Chief Scientific OfficerSoldunder a preset trading plan
- Date
- 5 August 2026
- Shares
- 2,207
- Price
- $123.99
- Value
- $273,646
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 16 November 2026 | Stein Steven H CMO & Head of Late-Stage Dev. | Sold under a preset trading plan | 576 | $121.98 | $70,260 |
| 16 November 2026 | CAGNONI PABLO J President, Global Head of R&D | Sold under a preset trading plan | 2,642 | $120.96 | $319,588 |
| 13 November 2026 | Heeson Lee EVP, Head of Incyte Intl | Sold under a preset trading plan | 10,694 | $120.82 | $1m |
| 6 November 2026 | Stein Steven H CMO & Head of Late-Stage Dev. | Sold under a preset trading plan | 240,193 | $118.39 | $28m |
| 3 November 2026 | Tray Thomas Principal Accounting Officer | Sold under a preset trading plan | 610 | $118.96 | $72,566 |
| 15 October 2026 | CAGNONI PABLO J President, Global Head of R&D | Sold under a preset trading plan | 2,642 | $112.71 | $297,780 |
| 15 September 2026 | CAGNONI PABLO J President, Global Head of R&D | Sold under a preset trading plan | 23,218 | $120.49 | $3m |
| 19 August 2026 | CAGNONI PABLO J President, Global Head of R&D | Sold under a preset trading plan | 10,801 | $125.56 | $1m |
| 12 August 2026 | CAGNONI PABLO J President, Global Head of R&D | Sold under a preset trading plan | 10,803 | $120.04 | $1m |
| 5 August 2026 | Mayes Patrick A EVP & Chief Scientific Officer | Sold under a preset trading plan | 2,207 | $123.99 | $273,646 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
How the boss is paid
William J. Meury was paid $32.1 million in 2025, about 110 times the typical employee’s pay.
The yearly bonus pays for per-share results:
No — it isn’t tied to per-share results.
The long-term stock award pays for per-share results:
Yes — it uses shareholder return.
Why it matters: new shares can grow total profit while each share earns less. Per-share goals pay the boss only when your slice grows.
From the proxy statement (the company’s yearly voting pack) filed 28 April 2026. Picked out automatically from the company’s own filing. Evidence, not our verdict.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Feb 2026, plus the 10-Q filed 29 Oct 2026 and 12 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
What changed in the risks this year
Companies must list what could hurt them each year. These are the parts that changed since last year’s report.
Changes in tax laws or regulations could adversely affect our results of operations, business and financial condition.
Could happenNew tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our results of operations, business and financial condition. For example, in July 2025, U.S. federal tax legislation commonly referred to as the One Big Beautiful Bill Act was enacted, which, among other things, allows domestic research and development expenditures to be expensed for tax years beginning on or after January 1, 2025, with retroactive elections for such expenditures paid or incurred in the two prior years but also increases the effective tax rate on foreign-derived deduction eligible income (formerly known as “foreign-derived intangible income”) for tax years beginning on or after January 1, 2026. As another example, in August 2022, the Inflation Reduction Act of 2022 was enacted, which, among other things, includes a new 15% alternative minimum tax on the adjusted financial statement income of certain large corporations for tax years beginning after December 31, 2022.
Read moreChanges in government pricing policies, including the enactment of “most favored nation” pricing legislation, could adversely affect our business.
Could happenOur revenue, results of operations, and cash flows could be materially and adversely affected by changes in government pricing policies, including recently proposed or enacted “most favored nation” (MFN) pricing legislation or executive actions. For example, an executive order issued on May 12, 2025, directed the Department of Health and Human Services to establish MFN price targets, and, if progress toward these targets is insufficient, to pursue rulemaking that could require sale of certain products in the U.S. at prices no higher than those in comparable developed nations. The extent, timing, and ultimate effect of this policy are uncertain, and we cannot predict the potential impact on our pricing, reimbursement, or profitability.
Read more
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
The company just reported its latest figures. The deep dive shows what they mean for the price you pay.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.